☰

Malathy Shekhar - Publications

Affiliations: 
Cancer Biology Wayne State University, Detroit, MI, United States 
Area:
Oncology, Molecular Biology
Tree Info Grants Similar researchers PubMed Report error

31 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Elayoubi J, Chi J, Mahmoud AA, Alloghbi A, Assad H, Shekhar M, Simon MS. A Review of Endocrine Therapy in Early-stage Breast Cancer: The Journey From Crudeness to Precision. American Journal of Clinical Oncology. PMID 36856249 DOI: 10.1097/COC.0000000000000993  0.392
2022 Haynes BM, Cunningham K, Shekhar MPV. RAD6 inhibition enhances paclitaxel sensitivity of triple negative breast cancer cells by aggravating mitotic spindle damage. Bmc Cancer. 22: 1073. PMID 36258187 DOI: 10.1186/s12885-022-10119-z  0.576
2022 Uddin MH, Zhou JY, Pimentel J, Patrick SM, Kim S, Shekhar MP, Wu GS. Proteomic Analysis Identifies p62/SQSTM1 as a Critical Player in PARP Inhibitor Resistance. Frontiers in Oncology. 12: 908603. PMID 35847859 DOI: 10.3389/fonc.2022.908603  0.349
2021 Gajan A, Sarma A, Kim S, Gurdziel K, Wu GS, Shekhar MP. Analysis of Adaptive Olaparib Resistance Effects on Cisplatin Sensitivity in Triple Negative Breast Cancer Cells. Frontiers in Oncology. 11: 694793. PMID 34367977 DOI: 10.3389/fonc.2021.694793  0.386
2021 Gajan A, Sarma A, Kim S, Gurdziel K, Wu GS, Shekhar MP. Analysis of Adaptive Olaparib Resistance Effects on Cisplatin Sensitivity in Triple Negative Breast Cancer Cells Frontiers in Oncology. 11. DOI: 10.3389/fonc.2021.694793  0.418
2019 Haynes B, Gajan A, Nangia-Makker P, Shekhar MP. RAD6B is a major mediator of triple negative breast cancer cisplatin resistance: Regulation of translesion synthesis/Fanconi anemia crosstalk and BRCA1 independence. Biochimica Et Biophysica Acta. Molecular Basis of Disease. 165561. PMID 31639439 DOI: 10.1016/j.bbadis.2019.165561  0.502
2019 Haynes B, Zhang Y, Liu F, Li J, Petit S, Kothayer H, Bao X, Westwell AD, Mao G, Shekhar MP. Corrigendum to "Gold nanoparticle conjugated Rad6 inhibitor induces cell death in triple negative breast cancer cells by inducing mitochondrial dysfunction and PARP-1 hyperactivation: Synthesis and characterization" [Nanomedicine 12 (3) (2016), 745-757]. Nanomedicine : Nanotechnology, Biology, and Medicine. PMID 30726707 DOI: 10.1016/J.Nano.2019.01.005  0.441
2018 Haagenson KK, Zhang JW, Xu Z, Shekhar MPV, Wu GS. Erratum: Functional analysis of MKP-1 and MKP-2 in breast cancer tamoxifen sensitivity. Oncotarget. 9: 35286. PMID 30443298 DOI: 10.18632/oncotarget.26258  0.637
2018 Saadat N, Liu F, Haynes B, Nangia-Makker P, Bao X, Li J, Polin L, Gupta S, Mao G, Shekhar MP. Nano-targeted Delivery of Rad6/Translesion Synthesis Inhibitor for Triple Negative Breast Cancer Therapy. Molecular Cancer Therapeutics. PMID 30242094 DOI: 10.1158/1535-7163.Mct-18-0364  0.49
2017 Haynes B, Sarma A, Nangia-Makker P, Shekhar MP. Breast cancer complexity: implications of intratumoral heterogeneity in clinical management. Cancer Metastasis Reviews. PMID 28752247 DOI: 10.1007/s10555-017-9684-y  0.366
2017 Sanders MA, Haynes B, Nangia-Makker P, Polin LA, Shekhar MP. Pharmacological targeting of Rad6 enzyme-mediated translesion synthesis overcomes resistance to platinum-based drugs. The Journal of Biological Chemistry. PMID 28490629 DOI: 10.1074/jbc.M117.792192  0.368
2016 Haynes B, Zhang Y, Li J, Petit S, Westwell A, Mao G, Shekhar M. Abstract P3-14-06: Evaluation of the therapeutic efficacy of a Rad6 small molecule inhibitor in triple negative breast cancer cells Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P3-14-06  0.596
2016 Haynes B, Cunningham K, Shekhar M. Abstract 3786: Rad6 inhibition enhances paclitaxel sensitivity of triple negative breast cancer cells by inducing mitotic spindle defects Cancer Research. 76: 3786-3786. DOI: 10.1158/1538-7445.Am2016-3786  0.607
2015 Haynes B, Zhang Y, Liu F, Li J, Petit S, Kothayer H, Bao X, Westwell AD, Mao G, Shekhar MP. Gold nanoparticle conjugated Rad6 inhibitor induces cell death in triple negative breast cancer cells by inducing mitochondrial dysfunction and PARP-1 hyperactivation: Synthesis and characterization. Nanomedicine : Nanotechnology, Biology, and Medicine. PMID 26563438 DOI: 10.1016/J.Nano.2015.10.010  0.579
2015 Haynes B, Kothayer H, Westwell A, Shekhar M. Abstract 1662: Therapeutic relevance of the Rad6/translesion synthesis pathway in BRCA1-related triple-negative breast cancer cells Cancer Research. 75: 1662-1662. DOI: 10.1158/1538-7445.Am2015-1662  0.547
2014 Rosner K, Adsule S, Haynes B, Kirou E, Kato I, Mehregan DR, Shekhar MP. Rad6 is a Potential Early Marker of Melanoma Development. Translational Oncology. PMID 24831578 DOI: 10.1016/j.tranon.2014.04.009  0.306
2014 Haagenson KK, Zhang JW, Xu Z, Shekhar MP, Wu GS. Functional analysis of MKP-1 and MKP-2 in breast cancer tamoxifen sensitivity. Oncotarget. 5: 1101-10. PMID 24658355 DOI: 10.18632/Oncotarget.1795  0.638
2014 Haynes B, Sanders M, Shekhar M. Abstract 820: Inhibition of Rad6 sensitizes triple negative breast cancer cells to platinum-based therapy Cancer Research. 74: 820-820. DOI: 10.1158/1538-7445.Am2014-820  0.547
2013 Kothayer H, Elshanawani AA, Abu Kull ME, El-Sabbagh OI, Shekhar MP, Brancale A, Jones AT, Westwell AD. Design, synthesis and in vitro anticancer evaluation of 4,6-diamino-1,3,5-triazine-2-carbohydrazides and -carboxamides. Bioorganic & Medicinal Chemistry Letters. 23: 6886-9. PMID 24153206 DOI: 10.1016/j.bmcl.2013.09.087  0.324
2013 Shekhar MP, Kato I, Nangia-Makker P, Tait L. Comedo-DCIS is a precursor lesion for basal-like breast carcinoma: identification of a novel p63/Her2/neu expressing subgroup. Oncotarget. 4: 231-41. PMID 23548208  0.521
2013 Nangia-Makker P, Raz T, Tait L, Shekhar MPV, Li H, Balan V, Makker H, Fridman R, Maddipati K, Raz A. Ocimum gratissimum retards breast cancer growth and progression and is a natural inhibitor of matrix metalloproteases Cancer Biology and Therapy. 14: 417-427. PMID 23380593 DOI: 10.4161/cbt.23762  0.448
2012 Haagenson KK, Tait L, Wang J, Shekhar MP, Polin L, Chen W, Wu GS. Cullin-3 protein expression levels correlate with breast cancer progression. Cancer Biology & Therapy. 13: 1042-6. PMID 22825334 DOI: 10.4161/Cbt.21046  0.638
2010 Shekhar MP, Biernat LA, Pernick N, Tait L, Abrams J, Visscher DW. Utility of DNA postreplication repair protein Rad6B in neoadjuvant chemotherapy response. Medical Oncology (Northwood, London, England). 27: 466-73. PMID 19466589 DOI: 10.1007/s12032-009-9235-7  0.321
2009 Ye CJ, Stevens JB, Liu G, Bremer SW, Jaiswal AS, Ye KJ, Lin MF, Lawrenson L, Lancaster WD, Kurkinen M, Liao JD, Gairola CG, Shekhar MP, Narayan S, Miller FR, et al. Genome based cell population heterogeneity promotes tumorigenicity: the evolutionary mechanism of cancer. Journal of Cellular Physiology. 219: 288-300. PMID 19115235 DOI: 10.1002/Jcp.21663  0.323
2008 Shekhar MP, Tait L, Pauley RJ, Wu GS, Santner SJ, Nangia-Makker P, Shekhar V, Nassar H, Visscher DW, Heppner GH, Miller FR. Comedo-ductal carcinoma in situ: A paradoxical role for programmed cell death. Cancer Biology & Therapy. 7: 1774-82. PMID 18787417  0.35
2007 Shekhar MP, Santner S, Carolin KA, Tait L. Direct involvement of breast tumor fibroblasts in the modulation of tamoxifen sensitivity. The American Journal of Pathology. 170: 1546-60. PMID 17456761 DOI: 10.2353/ajpath.2007.061004  0.408
2007 Nangia-Makker P, Tait L, Shekhar MP, Palomino E, Hogan V, Piechocki MP, Funasaka T, Raz A. Inhibition of breast tumor growth and angiogenesis by a medicinal herb: Ocimum gratissimum. International Journal of Cancer. 121: 884-94. PMID 17437270 DOI: 10.1002/ijc.22733  0.541
2006 Shekhar MP, Tait L, Gerard B. Essential role of T-cell factor/beta-catenin in regulation of Rad6B: a potential mechanism for Rad6B overexpression in breast cancer cells. Molecular Cancer Research : McR. 4: 729-45. PMID 17050667 DOI: 10.1158/1541-7786.MCR-06-0136  0.457
2004 Shekhar MP, Nangia-Makker P, Tait L, Miller F, Raz A. Alterations in galectin-3 expression and distribution correlate with breast cancer progression: functional analysis of galectin-3 in breast epithelial-endothelial interactions. The American Journal of Pathology. 165: 1931-41. PMID 15579437 DOI: 10.1016/S0002-9440(10)63245-2  0.564
2003 Shekhar MP, Pauley R, Heppner G. Host microenvironment in breast cancer development: extracellular matrix-stromal cell contribution to neoplastic phenotype of epithelial cells in the breast. Breast Cancer Research : Bcr. 5: 130-5. PMID 12793893 DOI: 10.1186/bcr580  0.415
2002 Shekhar MP, Lyakhovich A, Visscher DW, Heng H, Kondrat N. Rad6 overexpression induces multinucleation, centrosome amplification, abnormal mitosis, aneuploidy, and transformation. Cancer Research. 62: 2115-24. PMID 11929833  0.442
Show low-probability matches.